Drugs / iCP-NI
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05740280 | Jan → Apr 2023 | — | Cellivery Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iCP-NI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05740280 ↗ |
| Action | Inhibit | “inhibits the interaction of nuclear transfer material proteins such as IATF (NF-BB, STAT, AP-1, NFAT) and importin alpha5” NCT05740280 ↗ |
| Modality | Peptide | “cell-penetrating peptide” NCT05740280 ↗ |
| Route | Intravenous | “intravenous injection” NCT05740280 ↗ |